Epizyme reported $71.07M in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US $ 88.54M 8.52M
Amarin AMRN:US $ 228M 8.85M
Amgen AMGN:US $ 5203M 1325M
Avrobio Inc AVRO:US $ 132.41M 29.25M
Biogen BIIB:US $ 2646.6M 897.3M
Bluebird Bio BLUE:US $ 81.5M 24.76M
Cerulean Pharma CERU:US $ 39.32M 12.36M
Daiichi Sankyo 4568:JP Y 658064M 4413M
Eisai 4523:JP Y 287815M 23426M
Epizyme EPZM:US $ 71.07M 6.36M
Exelixis EXEL:US $ 627M 96.27M
Gilead Sciences GILD:US $ 7000M 2704M
GlaxoSmithKline GSK:LN 646500M 450200M
Glaxosmithkline GSK:US $ 6465M 4502M
Karyopharm Therapeutics KPTI:US $ 82.25M 71.01M
Macrogenics MGNX:US $ 21.47M 25.86M
Mirati Therapeutics MRTX:US $ 245.51M 47.91M
Novartis NVS:US $ 3625M 10227M
Novartis NOVN:VX SF 3625M 10227M
Regeneron Pharmaceuticals REGN:US $ 3395.1M 49.4M
Seattle Genetics SGEN:US $ 364.87M 103.88M
Spectrum Pharmaceuticals SPPI:US $ 25.51M 53.17M
Vertex Pharmaceuticals VRTX:US $ 8702.2M 1102.1M
Xencor XNCR:US $ 49.41M 28.86M